Headlands Technologies LLC Purchases New Holdings in Pfizer Inc. (NYSE:PFE)

Headlands Technologies LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 41,111 shares of the biopharmaceutical company’s stock, valued at approximately $1,184,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Briaud Financial Planning Inc purchased a new position in Pfizer in the 3rd quarter valued at about $30,000. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC lifted its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC lifted its stake in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the 4th quarter worth approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.6 %

Pfizer stock opened at $25.40 on Friday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a 50 day moving average price of $26.96 and a 200 day moving average price of $28.39. The company has a market capitalization of $143.83 billion, a PE ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analysts Set New Price Targets

A number of research analysts have weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.